Equirest Tablet contains a combination of Chlordiazepoxide 5 mg and Clidinium 2.5 mg, formulated to provide anxiolytic and anticholinergic effects. Chlordiazepoxide, a benzodiazepine derivative, exerts its therapeutic action by enhancing the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) activity in the central nervous system, resulting in anxiolytic, sedative, muscle relaxant, and anticonvulsant properties. Clidinium is an anticholinergic agent that reduces gastrointestinal motility and secretions by blocking muscarinic receptors, thereby alleviating abdominal cramps and spasms. The combination is primarily indicated for the management of anxiety associated with gastrointestinal disorders such as irritable bowel syndrome, peptic ulcer disease, and other functional bowel disturbances where anxiety exacerbates symptoms. Equirest Tablet aids in reducing both psychological tension and gastrointestinal discomfort concurrently. The dosage should be individualized according to patient response and clinical condition, typically administered orally before meals or as directed by a healthcare professional. Caution is advised in patients with a history of hypersensitivity to benzodiazepines or anticholinergic agents, glaucoma, myasthenia gravis, or prostatic hypertrophy. Use during pregnancy and lactation should be avoided unless clearly necessary. Adverse effects may include drowsiness, dry mouth, blurred vision, and dizziness.